NCT04574453View on ClinicalTrials.gov

Study To Assess The Efficacy And Safety Of The Medical Device Iracross Versus Iraline Administered Intra-Articular To Patients With Knee Osteoarthritis

NACompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions

Osteoarthritis, Knee

Interventions

DEVICE

Iracross

Administration of max 2ml of Iracross at first visit

DEVICE

Iraline

Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need

Trial Locations (1)

300211

Fizio Center, Timișoara

All Listed Sponsors

collaborator

Opera CRO, a TIGERMED Group Company

OTHER

lead

I.R.A. Istituto Ricerche Applicate S.p.A.

NETWORK

NCT04574453 - Study To Assess The Efficacy And Safety Of The Medical Device Iracross Versus Iraline Administered Intra-Articular To Patients With Knee Osteoarthritis | Biotech Hunter | Biotech Hunter